Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received int...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ad72d1dea1af4a47b0913630a94c2fa5 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ad72d1dea1af4a47b0913630a94c2fa52021-12-02T04:41:58ZShort-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab1177-5483https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa52017-05-01T00:00:00Zhttps://www.dovepress.com/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). Patients and methods: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group. Patient outcomes were examined at 1 week and 1 month postinjection. Results: Both groups comprised 27 eyes from 27 patients. There was a significant decrease in central macular thickness (CMT) at 1 week and 1 month postinjection in both groups. There was also a significant improvement in best-corrected visual acuity (BCVA) at 1 week and 1 month postinjection in the treatment-naïve group and 1 month in the switching group. Younger age was associated with a good BCVA at 1 month postinjection in the switching group, and the absence of epiretinal membrane was associated with a reduction in CMT at 1 month postinjection in the switching group. Conclusion: IVA is temporarily effective for treating ME due to BRVO regardless of a history of IVR use. Keywords: BRVO, IVR, IVA, switch Sakanishi YUsui-Ouchi ATamaki KMashimo KIto REbihara NDove Medical Pressarticleafliberceptranibizumabswitchbranch retinal vein occlusionmacular edemaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 829-834 (2017) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
aflibercept ranibizumab switch branch retinal vein occlusion macular edema Ophthalmology RE1-994 |
spellingShingle |
aflibercept ranibizumab switch branch retinal vein occlusion macular edema Ophthalmology RE1-994 Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
description |
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). Patients and methods: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group. Patient outcomes were examined at 1 week and 1 month postinjection. Results: Both groups comprised 27 eyes from 27 patients. There was a significant decrease in central macular thickness (CMT) at 1 week and 1 month postinjection in both groups. There was also a significant improvement in best-corrected visual acuity (BCVA) at 1 week and 1 month postinjection in the treatment-naïve group and 1 month in the switching group. Younger age was associated with a good BCVA at 1 month postinjection in the switching group, and the absence of epiretinal membrane was associated with a reduction in CMT at 1 month postinjection in the switching group. Conclusion: IVA is temporarily effective for treating ME due to BRVO regardless of a history of IVR use. Keywords: BRVO, IVR, IVA, switch |
format |
article |
author |
Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N |
author_facet |
Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N |
author_sort |
Sakanishi Y |
title |
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
title_short |
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
title_full |
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
title_fullStr |
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
title_full_unstemmed |
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
title_sort |
short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab |
publisher |
Dove Medical Press |
publishDate |
2017 |
url |
https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa5 |
work_keys_str_mv |
AT sakanishiy shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT usuiouchia shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT tamakik shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT mashimok shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT itor shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT ebiharan shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab |
_version_ |
1718401143777787904 |